For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
|Videos|June 19, 2014
Results of the ECOG E3805 Study
Author(s)Michael J. Morris
Michael J. Morris, MD, GU Oncologists, Memorial Sloan Kettering Cancer Center, discusses the results of the ECOG E3805 study, which examined chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer.
Advertisement
Michael J. Morris, MD, GU Oncologists, Memorial Sloan Kettering Cancer Center, discusses the results of the ECOG E3805 study, which examined chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer.
Clinical Pearls:
- Patients in this trial were randomized to receive hormone therapy alone or hormone therapy plus 6 cycles of docetaxel.
- Median OS was 57.6 months in the hormone therapy plus docetaxel arm and 44.0 months in the hormone therapy arm.
- Median time to clinical progression was greater in the docetaxel plus hormone therapy arm (32.7 months) than the hormone therapy-only arm (19.8 months).
<<<
Advertisement
Related to this article
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5